FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 338:853-860 March 26, 1998 Number 13 Next

	Full Text PDF Editorial by Hirschel, B. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background and Methods National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS). To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997.

Results Mortality among the patients declined from 29.4 per 100 person-years in 1995 to 8.8 per 100 person-years in the second quarter of 1997. There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV. The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997. In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality. Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit. Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid.

Conclusions The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.

Source Information

From Northwestern University Medical School, Chicago (F.J.P.); the Health Research Network of Apache Medical Systems, Chicago (K.M.D., D.J.A.); the Centers for Disease Control and Prevention, Atlanta (A.C.M., G.A.S., S.D.H.); Oregon Health Sciences University, Portland (M.O.L.); and the State University of New York, Stony Brook (J.F.).

Address reprint requests to Dr. Palella at Northwestern University Medical School, 303 E. Superior St., Passavant Pavilion, Rm. 828, Chicago, IL 60611-0949.

Full Text of this Article

Related Letters:

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
Michaels S. H., Clark R., Kissinger P.
Extract | Full Text  
N Engl J Med 1998; 339:405-406, Aug 6, 1998. Correspondence

Efavirenz in HIV Infection
Casado J. L., Moreno S., Manion D. J., Ruiz N. M., Staszewski S.
Extract | Full Text  
N Engl J Med 2000; 342:1290-1291, Apr 27, 2000. Correspondence

This article has been cited by other articles:

• Fabbiani, M., Di Giambenedetto, S., Bracciale, L., Bacarelli, A., Ragazzoni, E., Cauda, R., Navarra, P., De Luca, A. (2009). Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 64: 109-117 [Abstract] [Full Text]  
• Jallow, S., Alabi, A., Sarge-Njie, R., Peterson, K., Whittle, H., Corrah, T., Jaye, A., Cotten, M., Vanham, G., McConkey, S. J., Rowland-Jones, S., Janssens, W. (2009). Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in The Gambia and Emergence of Drug-Resistant Variants. J. Clin. Microbiol. 47: 2200-2208 [Abstract] [Full Text]  
• Park-Wyllie, L. Y, Kam, D., Bayoumi, A. M (2009). The Adherence Support Gap: The `Ideal' Versus `Reality' of Antiretroviral Adherence Support Provided by HIV Health Providers in Clinical Practice. The Annals of Pharmacotherapy 43: 1036-1044 [Abstract] [Full Text]  
• Lynam, I., Catley, D., Goggin, K., Rabinowitz, J. L., Gerkovich, M. M., Williams, K., Wright, J., & MOTIV8, (2009). Autonomous Regulation and Locus of Control as Predictors of Antiretroviral Medication Adherence. J Health Psychol 14: 578-586 [Abstract]  
• Balsalobre, P., Diez-Martin, J. L., Re, A., Michieli, M., Ribera, J. M., Canals, C., Rosselet, A., Conde, E., Varela, R., Cwynarski, K., Gabriel, I., Genet, P., Guillerm, G., Allione, B., Ferrant, A., Biron, P., Espigado, I., Serrano, D., Sureda, A. (2009). Autologous Stem-Cell Transplantation in Patients With HIV-Related Lymphoma. JCO 27: 2192-2198 [Abstract] [Full Text]  
• Cain, L. E., Cole, S. R., Greenland, S., Brown, T. T., Chmiel, J. S., Kingsley, L., Detels, R. (2009). Effect of Highly Active Antiretroviral Therapy on Incident AIDS Using Calendar Period as an Instrumental Variable. Am J Epidemiol 169: 1124-1132 [Abstract] [Full Text]  
• Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., Rourke, S. B., Gill, M. J., Bosch, R. J., Martin, J. N., Klein, M. B., Jacobson, L. P., Rodriguez, B., Sterling, T. R., Kirk, G. D., Napravnik, S., Rachlis, A. R., Calzavara, L. M., Horberg, M. A., Silverberg, M. J., Gebo, K. A., Goedert, J. J., Benson, C. A., Collier, A. C., Van Rompaey, S. E., Crane, H. M., McKaig, R. G., Lau, B., Freeman, A. M., Moore, R. D., the NA-ACCORD Investigators, (2009). Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. NEJM 360: 1815-1826 [Abstract] [Full Text]  
• Wood, E., Kerr, T., Marshall, B. D L, Li, K., Zhang, R., Hogg, R. S, Harrigan, P R., Montaner, J. S G (2009). Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 338: b1649-b1649 [Abstract] [Full Text]  
• Yang, H.-C., Shen, L., Siliciano, R. F., Pomerantz, J. L. (2009). Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc. Natl. Acad. Sci. USA 106: 6321-6326 [Abstract] [Full Text]  
• Woldemichael, G., Christiansen, D., Thomas, S., Benbow, N. (2009). Demographic Characteristics and Survival With AIDS: Health Disparities in Chicago, 1993-2001. Am. J. Public Health 99: S118-S123 [Abstract] [Full Text]  
• Zhang, S., Carper, M. J., Lei, X., Cade, W. T., Yarasheski, K. E., Ramanadham, S. (2009). Protease inhibitors used in the treatment of HIV+ induce {beta}-cell apoptosis via the mitochondrial pathway and compromise insulin secretion. Am. J. Physiol. Endocrinol. Metab. 296: E925-E935 [Abstract] [Full Text]  
• Hue, S., Gifford, R. J., Dunn, D., Fernhill, E., Pillay, D., on Behalf of the UK Collaborative Group on HIV Dru, (2009). Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naive Individuals. J. Virol. 83: 2645-2654 [Abstract] [Full Text]  
• Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., Pomerantz, R. J. (2009). The Challenge of Finding a Cure for HIV Infection. Science 323: 1304-1307 [Abstract] [Full Text]  
• Silverberg, M. J., Leyden, W., Hurley, L., Go, A. S., Quesenberry, C. P. Jr., Klein, D., Horberg, M. A. (2009). Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection. ANN INTERN MED 150: 301-313 [Abstract] [Full Text]  
• Vellozzi, C., Brooks, J. T., Bush, T. J., Conley, L. J., Henry, K., Carpenter, C. C. J., Overton, E. T., Hammer, J., Wood, K., Holmberg, S. D., the SUN Study Investigators, (2009). The Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN Study). Am J Epidemiol 169: 642-652 [Abstract] [Full Text]  
• Wang, X., Chai, H., Lin, P. H., Yao, Q., Chen, C. (2009). Roles and Mechanisms of Human Immunodeficiency Virus Protease Inhibitor Ritonavir and Other Anti-Human Immunodeficiency Virus Drugs in Endothelial Dysfunction of Porcine Pulmonary Arteries and Human Pulmonary Artery Endothelial Cells. Am. J. Pathol. 174: 771-781 [Abstract] [Full Text]  
• Martinelli, P., Agangi, A., Sansone, M., Napolitano, R., Maruotti, G. M. (2009). An important clinical lesson from a patient infected with HIV with diabetic nephropathy and retinopathy. BMJ Case Reports 2009: bcr0620080200-bcr0620080200 [Abstract] [Full Text]  
• Hutter, G., Nowak, D., Mossner, M., Ganepola, S., Mussig, A., Allers, K., Schneider, T., Hofmann, J., Kucherer, C., Blau, O., Blau, I. W., Hofmann, W. K., Thiel, E. (2009). Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. NEJM 360: 692-698 [Abstract] [Full Text]  
• Levy, J. A. (2009). Not an HIV Cure, but Encouraging New Directions. NEJM 360: 724-725 [Full Text]  
• Beadsworth, M B J, Cohen, D, Ratcliffe, L, Jenkins, N, Taylor, W, Campbell, F, Beeching, N J, Azadeh, B (2009). Autopsies in HIV: still identifying missed diagnoses. Int J STD AIDS 20: 84-86 [Abstract] [Full Text]  
• Colucci, P., Pottage, J. C., Robison, H., Turgeon, J., Ducharme, M. P. (2009). Effect of a Single Dose of Ritonavir on the Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered in Healthy Volunteers. Antimicrob. Agents Chemother. 53: 646-650 [Abstract] [Full Text]  
• Jacobson, J. M., Kuritzkes, D. R., Godofsky, E., DeJesus, E., Larson, J. A., Weinheimer, S. P., Lewis, S. T. (2009). Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults. Antimicrob. Agents Chemother. 53: 450-457 [Abstract] [Full Text]  
• Crough, T., Khanna, R. (2009). Immunobiology of Human Cytomegalovirus: from Bench to Bedside. Clin. Microbiol. Rev. 22: 76-98 [Abstract] [Full Text]  
• Powell, K., Davis, J. L., Morris, A. M., Chi, A., Bensley, M. R., Huang, L. (2009). Survival for Patients With HIV Admitted to the ICU Continues to Improve in the Current Era of Combination Antiretroviral Therapy. Chest 135: 11-17 [Abstract] [Full Text]  
• Fan, M. D, Maslow, B.-S., Santoro, N., Schoenbaum, E. (2008). HIV and the menopause. Menopause Int 14: 163-168 [Abstract] [Full Text]  
• Hull, M. W., Phillips, P., Montaner, J. S. G. (2008). Changing Global Epidemiology of Pulmonary Manifestations of HIV/AIDS. Chest 134: 1287-1298 [Abstract] [Full Text]  
• Guaraldi, G., Cocchi, S., Motta, A., Ciaffi, S., Codeluppi, M., Bonora, S., Di Benedetto, F., Masetti, M., Floridia, M., Baroncelli, S., Pinetti, D., D'Avolio, A., Bertolini, A., Esposito, R. (2008). A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. J Antimicrob Chemother 62: 1356-1364 [Abstract] [Full Text]  
• Bedimo, R. J. (2008). Body-Fat Abnormalities in Patients With HIV: Progress and Challenges. J Int Assoc Physicians AIDS Care (Chic Ill) 7: 292-305 [Abstract]  
• Huang, F., Koenen-Bergmann, M., MacGregor, T. R., Ring, A., Hattox, S., Robinson, P. (2008). Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. Antimicrob. Agents Chemother. 52: 4300-4307 [Abstract] [Full Text]  
• He, Y., Liu, S., Li, J., Lu, H., Qi, Z., Liu, Z., Debnath, A. K., Jiang, S. (2008). Conserved Salt Bridge between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 gp41 Core Structure Is Critical for Virus Entry and Inhibition. J. Virol. 82: 11129-11139 [Abstract] [Full Text]  
• Likatavicius, G, Klavs, I, Devaux, I, Alix, J, Nardone, A (2008). An increase in newly diagnosed HIV cases reported among men who have sex with men in Europe, 2000-6: implications for a European public health strategy. Sex. Transm. Infect. 84: 499-505 [Abstract] [Full Text]  
• Grant, P., Wong, E. C., Rode, R., Shafer, R., De Luca, A., Nadler, J., Hawkins, T., Cohen, C., Harrington, R., Kempf, D., Zolopa, A. (2008). Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores. Antimicrob. Agents Chemother. 52: 4050-4056 [Abstract] [Full Text]  
• Joos, B., Fischer, M., Kuster, H., Pillai, S. K., Wong, J. K., Boni, J., Hirschel, B., Weber, R., Trkola, A., Gunthard, H. F., The Swiss HIV Cohort Study, (2008). HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc. Natl. Acad. Sci. USA 105: 16725-16730 [Abstract] [Full Text]  
• Duvivier, C., Ghosn, J., Assoumou, L., Soulie, C., Peytavin, G., Calvez, V., Genin, M. A., Molina, J.-M., Bouchaud, O., Katlama, C., Costagliola, D., on behalf of the ANRS 121 study group, (2008). Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. J Antimicrob Chemother 62: 797-808 [Abstract] [Full Text]  
• Baekken, M., Os, I., Sandvik, L., Oektedalen, O. (2008). Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant 23: 3130-3137 [Abstract] [Full Text]  
• Kitahata, M. M, Rodriguez, B., Haubrich, R., Boswell, S., Mathews, W C., Lederman, M. M, Lober, W. B, Van Rompaey, S. E, Crane, H. M, Moore, R. D, Bertram, M., Kahn, J. O, Saag, M. S (2008). Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol 37: 948-955 [Full Text]  
• Bartlett, J. G., Branson, B. M., Fenton, K., Hauschild, B. C., Miller, V., Mayer, K. H. (2008). Opt-Out Testing for Human Immunodeficiency Virus in the United States: Progress and Challenges. JAMA 300: 945-951 [Abstract] [Full Text]  
• Torriani, F. J., Komarow, L., Parker, R. A., Cotter, B. R., Currier, J. S., Dube, M. P., Fichtenbaum, C. J., Gerschenson, M., Mitchell, C. K.C., Murphy, R. L., Squires, K., Stein, J. H., for the ACTG 5152s Study Team, (2008). Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 52: 569-576 [Abstract] [Full Text]  
• Brown, T. T. (2008). Approach to the Human Immunodeficiency Virus-Infected Patient with Lipodystrophy. J. Clin. Endocrinol. Metab. 93: 2937-2945 [Abstract] [Full Text]  
• Lowe, S M, Kocjan, G I, Edwards, S G, Miller, R F (2008). Diagnostic yield of fine-needle aspiration cytology in HIV-infected patients with lymphadenopathy in the era of highly active antiretroviral therapy. Int J STD AIDS 19: 553-556 [Abstract] [Full Text]  
• Watson, K. M., Buckheit, C. E., Buckheit, R. W. Jr. (2008). Comparative Evaluation of Virus Transmission Inhibition by Dual-Acting Pyrimidinedione Microbicides Using the Microbicide Transmission and Sterilization Assay. Antimicrob. Agents Chemother. 52: 2787-2796 [Abstract] [Full Text]  
• Van der Bij, A. K., Dukers, N. H. T. M., Coutinho, R. A., Fennema, H. S. A. (2008). Low HIV-testing rates and awareness of HIV infection among high-risk heterosexual STI clinic attendees in The Netherlands. Eur J Public Health 18: 376-379 [Abstract] [Full Text]  
• Jabs, D. A. (2008). AIDS and Ophthalmology, 2008. Arch Ophthalmol 126: 1143-1146 [Full Text]  
• Schillaci, G., De Socio, G. V.L., Pucci, G., Mannarino, M. R., Helou, J., Pirro, M., Mannarino, E. (2008). Aortic Stiffness in Untreated Adult Patients With Human Immunodeficiency Virus Infection. Hypertension 52: 308-313 [Abstract] [Full Text]  
• Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Nguyen, B.-Y., Teppler, H., the BENCHMRK Study Teams, (2008). Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. NEJM 359: 339-354 [Abstract] [Full Text]  
• Havlir, D. V. (2008). HIV Integrase Inhibitors -- Out of the Pipeline and into the Clinic. NEJM 359: 416-418 [Full Text]  
• Stein, J. H., Hadigan, C. M., Brown, T. T., Chadwick, E., Feinberg, J., Friis-Moller, N., Ganesan, A., Glesby, M. J., Hardy, D., Kaplan, R. C., Kim, P., Lo, J., Martinez, E., Sosman, J. M., for Working Group 6, (2008). Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients. Circulation 118: e54-e60 [Full Text]  
• Thirumurthy, H., Zivin, J. G., Goldstein, M. (2008). The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya. J. Human Resources 43: 511-552 [Abstract]  
• Battegay, M., Fehr, J., Fluckiger, U., Elzi, L. (2008). Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother 62: 41-44 [Abstract] [Full Text]  
• Lacerda, H R, Kitner, D (2008). Mortality of the elderly is still exceedingly high at diagnosis of AIDS despite favourable outcomes after highly active antiretroviral therapy in Recife, Brazil. Int J STD AIDS 19: 450-454 [Abstract] [Full Text]  
• He, Y., Cheng, J., Li, J., Qi, Z., Lu, H., Dong, M., Jiang, S., Dai, Q. (2008). Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors. J. Virol. 82: 6349-6358 [Abstract] [Full Text]  
• Nold, M. F., Nold-Petry, C. A., Pott, G. B., Zepp, J. A., Saavedra, M. T., Kim, S.-H., Dinarello, C. A. (2008). Endogenous IL-32 Controls Cytokine and HIV-1 Production. J. Immunol. 181: 557-565 [Abstract] [Full Text]  
• Hruz, P. W., Yan, Q., Struthers, H., Jay, P. Y. (2008). HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. FASEB J. 22: 2161-2167 [Abstract] [Full Text]  
• Dagogo-Jack, S. (2008). HIV Therapy and Diabetes Risk. Diabetes Care 31: 1267-1268 [Full Text]  
• Delpierre, C., Lauwers-Cances, V., Pugliese, P., Poizot-Martin, I., Billaud, E, Duvivier, C., Yazdanpanah, Y., Cuzin, L., the nadis group, (2008). Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people. Eur J Public Health 18: 345-347 [Abstract] [Full Text]  
• Torpey, K., Kasonde, D., Goma, F. (2008). The experience of patients taking the lopinavir/ritonavir (LPV/r) tablet compared with the LPV/r soft-gel capsule in Zambia. Int J STD AIDS 19: 1-4 [Abstract] [Full Text]  
• Kline, E. R., Kleinhenz, D. J., Liang, B., Dikalov, S., Guidot, D. M., Hart, C. M., Jones, D. P., Sutliff, R. L. (2008). Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration. Am. J. Physiol. Heart Circ. Physiol. 294: H2792-H2804 [Abstract] [Full Text]  
• Patel, P., Hanson, D. L., Sullivan, P. S., Novak, R. M., Moorman, A. C., Tong, T. C., Holmberg, S. D., Brooks, J. T., for the Adult and Adolescent Spectrum of Disease P, (2008). Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992-2003. ANN INTERN MED 148: 728-736 [Abstract] [Full Text]  
• van der Lugt, J., Autar, R. S., Ubolyam, S., Garcia, E. F., Sankote, J., Avihingson, A., Chuenyam, T., Cooper, D. A., Lange, J., Phanuphak, P., Wit, F., Ruxrungtham, K., Burger, D., on behalf of the HIV-NAT 019 Study Team, (2008). Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother 61: 1145-1153 [Abstract] [Full Text]  
• Kapogiannis, B. G., Soe, M. M., Nesheim, S. R., Sullivan, K. M., Abrams, E., Farley, J., Palumbo, P., Koenig, L. J., Bulterys, M. (2008). Trends in Bacteremia in the Pre- and Post-Highly Active Antiretroviral Therapy Era Among HIV-Infected Children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Pediatrics 121: e1229-e1239 [Abstract] [Full Text]  
• He, Y., Xiao, Y., Song, H., Liang, Q., Ju, D., Chen, X., Lu, H., Jing, W., Jiang, S., Zhang, L. (2008). Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor. J. Biol. Chem. 283: 11126-11134 [Abstract] [Full Text]  
• Margerison, E. S., Maguire, M., Pillay, D., Cane, P., Elston, R. C. (2008). The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication. J Antimicrob Chemother 61: 786-791 [Abstract] [Full Text]  
• Lawn, S. D., Wilkinson, R. J., Lipman, M. C. I., Wood, R. (2008). Immune Reconstitution and "Unmasking" of Tuberculosis during Antiretroviral Therapy. Am. J. Respir. Crit. Care Med. 177: 680-685 [Abstract] [Full Text]  
• Merenstein, D. J., Schneider, M. F., Cox, C., Schwartz, R., Weber, K., Robison, E., Gandhi, M., Richardson, J., Plankey, M. W. (2008). Association Between Living With Children and Adherence to Highly Active Antiretroviral Therapy in the Women's Interagency HIV Study. Pediatrics 121: e787-e793 [Abstract] [Full Text]  
• Pastakia, S. D, Corbett, A. H, Raasch, R. H, Napravnik, S., Correll, T. A (2008). Frequency of HIV-Related Medication Errors and Associated Risk Factors in Hospitalized Patients. The Annals of Pharmacotherapy 42: 491-497 [Abstract] [Full Text]  
• Burgoyne, R. W., Tan, D. H. S. (2008). Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother 61: 469-473 [Abstract] [Full Text]  
• Garcia-Gasco, P., Maida, I., Blanco, F., Barreiro, P., Martin-Carbonero, L., Vispo, E., Gonzalez-Lahoz, J., Soriano, V. (2008). Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 61: 699-704 [Abstract] [Full Text]  
• Ramia, S, Mokhbat, J, Ramlawi, F, El-Zaatari, M (2008). Occult hepatitis B virus infection in HIV-infected Lebanese patients with isolated antibodies to hepatitis B core antigen. Int J STD AIDS 19: 197-199 [Abstract] [Full Text]  
• Pialoux, G., Quercia, R. P., Gahery, H., Daniel, N., Slama, L., Girard, P.-M., Bonnard, P., Rozenbaum, W., Schneider, V., Salmon, D., Guillet, J.-G. (2008). Immunological Responses and Long-Term Treatment Interruption after Human Immunodeficiency Virus Type 1 (HIV-1) Lipopeptide Immunization of HIV-1-Infected Patients: the LIPTHERA Study. CVI 15: 562-568 [Abstract] [Full Text]  
• Carper, M. J., Cade, W. T., Cam, M., Zhang, S., Shalev, A., Yarasheski, K. E., Ramanadham, S. (2008). HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 294: E558-E567 [Abstract] [Full Text]  
• Hodder, S. (2008). Know Your Patient: What Conditions Affect Initial HIV Treatment Success?. J Int Assoc Physicians AIDS Care (Chic Ill) 7: S5-S9 [Abstract]  
• Lambert-Niclot, S., Flandre, P., Canestri, A., Peytavin, G., Blanc, C., Agher, R., Soulie, C., Wirden, M., Katlama, C., Calvez, V., Marcelin, A.-G. (2008). Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir. Antimicrob. Agents Chemother. 52: 491-496 [Abstract] [Full Text]  
• Connolly, N. C., Whiteside, T. L., Wilson, C., Kondragunta, V., Rinaldo, C. R., Riddler, S. A. (2008). Therapeutic Immunization with Human Immunodeficiency Virus Type 1 (HIV-1) Peptide-Loaded Dendritic Cells Is Safe and Induces Immunogenicity in HIV-1-Infected Individuals. CVI 15: 284-292 [Abstract] [Full Text]  
• Chiao, E. Y., Giordano, T. P., Richardson, P., El-Serag, H. B. (2008). Human Immunodeficiency Virus-Associated Squamous Cell Cancer of the Anus: Epidemiology and Outcomes in the Highly Active Antiretroviral Therapy Era. JCO 26: 474-479 [Abstract] [Full Text]  
• Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., Kano, M., Ikeda, S., Matsuoka, M. (2008). Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). J. Virol. 82: 764-774 [Abstract] [Full Text]  
• Mok, S., Minson, Q. (2008). Drug-related problems in hospitalized patients with HIV infection. Am J Health Syst Pharm 65: 55-59 [Abstract] [Full Text]  
• Shechter, S. M., Bailey, M. D., Schaefer, A. J., Roberts, M. S. (2008). The Optimal Time to Initiate HIV Therapy Under Ordered Health States. Operations Research 56: 20-33 [Abstract]  
• Lehtovirta, P., Paavonen, J., Heikinheimo, O. (2008). Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected women. Int J STD AIDS 19: 37-41 [Abstract] [Full Text]  
• Staib, P., Lermann, U., Bla -Warmuth, J., Degel, B., Wurzner, R., Monod, M., Schirmeister, T., Morschhauser, J. (2008). Tetracycline-Inducible Expression of Individual Secreted Aspartic Proteases in Candida albicans Allows Isoenzyme-Specific Inhibitor Screening. Antimicrob. Agents Chemother. 52: 146-156 [Abstract] [Full Text]